Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
May 26, 2022 10:15 ET
|
Revive Therapeutics Ltd.
The Company received positive comments from the FDA to determine potential new clinical endpoints to support Emergency Use Authorization TORONTO, May 26, 2022 (GLOBE NEWSWIRE) -- Revive...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
May 16, 2022 10:48 ET
|
Revive Therapeutics Ltd.
TORONTO, May 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
April 25, 2022 16:42 ET
|
Revive Therapeutics Ltd.
TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19
April 18, 2022 09:43 ET
|
Revive Therapeutics Ltd.
TORONTO, April 18, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
April 11, 2022 17:54 ET
|
Revive Therapeutics Ltd.
TORONTO, April 11, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
March 29, 2022 08:45 ET
|
Revive Therapeutics Ltd.
Expected to seek DSMB approval to proceed with EUA application to the FDA in Q2-2022 Ongoing regulatory package activities for submission to international regulatory authorities for drug approvals ...
Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation
February 15, 2022 16:26 ET
|
Revive Therapeutics Ltd.
TORONTO, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
February 14, 2022 06:00 ET
|
Revive Therapeutics Ltd.
Ethics Committee approval to proceed with Phase 3 clinical trial in Turkey13 clinical sites selected to date in Turkey TORONTO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive”...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
January 18, 2022 21:02 ET
|
Revive Therapeutics Ltd.
701 subjects dosed to dateInitiating enrollment activities in Turkey as part of its clinical diversification plans to support global regulatory approvals On-track to complete enrollment in Q1-2022 and...
Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs
January 17, 2022 08:17 ET
|
Revive Therapeutics Ltd.
IRB approval to initiate Phase 2 study for methamphetamine abuse disorders Advancing psilocybin oral thin film, microneedle patch and biosynthesis programs TORONTO, Jan. 17, 2022 ...